CY1112135T1 - Ανταγωνιστες υποδοχεα il-8 - Google Patents

Ανταγωνιστες υποδοχεα il-8

Info

Publication number
CY1112135T1
CY1112135T1 CY20111100624T CY111100624T CY1112135T1 CY 1112135 T1 CY1112135 T1 CY 1112135T1 CY 20111100624 T CY20111100624 T CY 20111100624T CY 111100624 T CY111100624 T CY 111100624T CY 1112135 T1 CY1112135 T1 CY 1112135T1
Authority
CY
Cyprus
Prior art keywords
competitive
receptors
competitive receptors
chemokine
interleukin
Prior art date
Application number
CY20111100624T
Other languages
English (en)
Inventor
Jakob Busch-Petersen
Michael R Palovich
Katherine L Widdowson
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CY1112135T1 publication Critical patent/CY1112135T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Αυτή η εφεύρεση σχετίζεται με νέες ενώσεις του Τύπου (I) ως (VII), και με συνθέσεις αυτών, που είναι χρήσιμες για τη θεραπεία καταστάσεων ασθενείας όπου μεσολαβεί η χημειοκίνη, Ιντερλευκίνη-8 (IL-8).
CY20111100624T 2002-10-29 2011-06-29 Ανταγωνιστες υποδοχεα il-8 CY1112135T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42195602P 2002-10-29 2002-10-29
EP03781400A EP1558259B1 (en) 2002-10-29 2003-10-28 Urea derivatives as IL-8 receptor antagonists

Publications (1)

Publication Number Publication Date
CY1112135T1 true CY1112135T1 (el) 2015-11-04

Family

ID=32230293

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100624T CY1112135T1 (el) 2002-10-29 2011-06-29 Ανταγωνιστες υποδοχεα il-8

Country Status (16)

Country Link
US (2) US20060040952A1 (el)
EP (2) EP2388006A1 (el)
JP (1) JP4843220B2 (el)
AR (1) AR041834A1 (el)
AT (1) ATE504300T1 (el)
AU (1) AU2003287219A1 (el)
CY (1) CY1112135T1 (el)
DE (1) DE60336672D1 (el)
DK (1) DK1558259T3 (el)
ES (1) ES2362357T3 (el)
MY (1) MY143477A (el)
PE (1) PE20040607A1 (el)
PT (1) PT1558259E (el)
SI (1) SI1558259T1 (el)
TW (1) TW200418812A (el)
WO (1) WO2004039775A2 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009039091A1 (en) * 2007-09-21 2009-03-26 Smithkline Beecham Corporation Method of treatment
US20070249625A1 (en) * 2004-10-20 2007-10-25 Jakob Busch-Petersen Il-8 Receptor Antagonists
BRPI0710232B8 (pt) * 2006-04-21 2021-05-25 Glaxosmithkline Llc composto antagonista do receptor de il-8, composição farmacêutica que compreende o dito composto e uso do mesmo para o tratamento de uma doença mediada por quimiocina
CN101495113A (zh) * 2006-04-21 2009-07-29 史密丝克莱恩比彻姆公司 Il-8受体拮抗剂
CL2007001829A1 (es) * 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
BR112017002060A2 (pt) * 2014-07-31 2017-12-26 Glaxosmithkline Ip Dev Ltd novo uso
CN111727184B (zh) * 2018-01-11 2022-06-28 深圳嘉科生物科技有限公司 Cxcr2拮抗剂
EP3998256A4 (en) * 2019-07-11 2023-07-19 Shenzhen Optimum Biological Technology Co., Ltd CRYSTALLINE FORM OF CXCR2 ANTAGONIST AND ITS USE

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1792156A (en) * 1928-01-17 1931-02-10 Gen Aniline Works Inc 5-halogen-2-amino-1-alkyloxy and 1-aralkyloxy-benzenes and intermediate products thereof and process of preparing them
US2363074A (en) * 1938-06-16 1944-11-21 Geigy Ag J R Halogen substituted acylamino sulphonic acids of the aromatic series and their manufacture
US2407309A (en) * 1942-02-04 1946-09-10 Squibb & Sons Inc Chemotherapeutic agents of the sulphonamide type
US2795610A (en) * 1955-03-31 1957-06-11 Du Pont Hydroxy-phenyl alkyl ureas
BE639588A (el) 1962-11-06
US3996253A (en) * 1966-01-11 1976-12-07 Minnesota Mining And Manufacturing Company Process for the preparation of color images
GB1210596A (en) 1967-04-06 1970-10-28 Armour Grocery Products Compan Antiseptic compositions
SE370866B (el) * 1968-03-21 1974-11-04 Ciba Geigy Ag
CH506240A (de) 1969-02-04 1971-04-30 Ciba Geigy Ag Verwendung von N-Hydroxyphenyl-N'-phenylharnstoffen zur Bekämpfung schädlicher Mikroorganismen ausserhalb der Textilindustrie
US3647819A (en) * 1969-09-19 1972-03-07 Sterling Drug Inc Indazolylphenylureas and indazolyl-phenylthioureas
FR2100943A1 (en) 1970-07-23 1972-03-24 Ici Ltd O-carboylcarbanilides from anthranilic acid and substd - isocyanates - immuno-suppressive agents
US4048333A (en) * 1971-08-23 1977-09-13 Medizinska Akademia Method for treating a picorna virus infection
DE2303761A1 (de) * 1973-01-26 1974-08-01 Henkel & Cie Gmbh Neue n,n'-disubstituierte thioharnstoffe, deren herstellung sowie verwendung als antimikrobielle substanzen
US4008326A (en) * 1973-12-26 1977-02-15 The Upjohn Company Substituted ureas and thioureas and pharmaceutical compositions thereof
US3932434A (en) * 1974-08-30 1976-01-13 Eli Lilly And Company N-2-(6-hydroxybenzothiazolyl)-N'-phenyl (or substituted phenyl) ureas
JPS5598152A (en) 1979-01-16 1980-07-25 Hokko Chem Ind Co Ltd Phenylurea derivative
DE2928485A1 (de) * 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
GB2079480B (en) 1980-07-08 1984-05-16 Kodak Ltd Heat-activated photographic and thermal recording processes employing precursor compounds
US4608205A (en) * 1983-03-09 1986-08-26 American Cyanamid Company Polyanionic benzene ureas
US4591604A (en) * 1984-03-28 1986-05-27 American Cyanamid Company Method of inhibiting the complement system by administering multisulfonated naphthalene ureas
DE68911203T2 (de) 1988-03-30 1994-04-14 Warner Lambert Co N-[[(2,6-disubstituierte)phenyl]N'- arylalkyl] Harnstoffe als antihypercholesterolemische und antiatherosclerotische Mittel.
US5215570A (en) * 1988-10-20 1993-06-01 Ciba-Geigy Corporation Sulfamoylphenylureas
US5290814A (en) * 1988-11-21 1994-03-01 Burroughs Wellcome Co. Anti-atherosclerotic diaryl compounds
US5206234A (en) * 1990-10-22 1993-04-27 Merck & Co., Inc. Benzolactam analogs as antagonists of cck
JPH05294935A (ja) * 1991-03-15 1993-11-09 Green Cross Corp:The アミノピリジン系化合物
AU659861B2 (en) 1991-09-10 1995-06-01 Sansho Seiyaku Co., Ltd. Preparation for promoting hair growth
JP2558427B2 (ja) * 1992-06-08 1996-11-27 ゼネラル・エレクトリック・カンパニイ ポリカーボネート上にシリコーンを堆積する方法
NZ250916A (en) * 1993-02-27 1995-08-28 Nihon Nohyaku Co Ltd N-heteroaryl-n'-phenylureas, their use as acat inhibitors
DK41193D0 (da) * 1993-04-07 1993-04-07 Neurosearch As Ionkanalaabnere
US5312831A (en) * 1993-05-12 1994-05-17 American Cyanamid Company Urethanes and ureas that induce cytokine production
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
US5547966A (en) 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
US5401758A (en) 1993-10-07 1995-03-28 Bristol-Myers Squibb Company Pyridinyl cyanoguanidine compounds
US5441984A (en) * 1994-01-06 1995-08-15 Eli Lilly And Company Urea, thiourea and guanidine derivatives
US5576335A (en) * 1994-02-01 1996-11-19 Nisshin Flour Milling Co., Ltd. Urea derivatives and their use as ACAT inhibitors
DE4413265A1 (de) * 1994-04-16 1995-10-19 Basf Ag Hydroxyphenylharnstoffe
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
WO1996025157A1 (en) * 1995-02-17 1996-08-22 Smithkline Beecham Corporation Il-8 receptor antagonists
US6005008A (en) * 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
US6211373B1 (en) * 1996-03-20 2001-04-03 Smithkline Beecham Corporation Phenyl urea antagonists of the IL-8 receptor
US6262113B1 (en) * 1996-03-20 2001-07-17 Smithkline Beecham Corporation IL-8 receptor antagonists
EP0915651A4 (en) * 1996-06-27 2001-10-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
JP2000515495A (ja) 1996-06-27 2000-11-21 スミスクライン・ビーチャム・コーポレイション Ｉｌ―８レセプターアンタゴニスト
WO1997049400A1 (en) * 1996-06-27 1997-12-31 Smithkline Beecham Corporation Il-8 receptor antagonists
JP2000513359A (ja) 1996-06-27 2000-10-10 スミスクライン・ビーチャム・コーポレイション Ｉｌ―８受容体拮抗薬
AU3409197A (en) * 1996-06-27 1998-01-14 Smithkline Beecham Corporation Il-8 receptor antagonists
JP2000515554A (ja) * 1996-08-06 2000-11-21 スミスクライン・ビーチャム・コーポレイション Ｉｌ―８受容体アンタゴニスト
WO1998005328A1 (en) 1996-08-06 1998-02-12 Smithkline Beecham Corporation Il-8 receptor antagonists
EP0957907A4 (en) * 1996-08-06 2001-08-16 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
WO1998006701A1 (en) 1996-08-15 1998-02-19 Smithkline Beecham Corporation Il-8 receptor antagonists
JP2000516621A (ja) * 1996-08-15 2000-12-12 スミスクライン・ビーチャム・コーポレイション Ｉｌ―８レセプターアンタゴニスト
JP2000516620A (ja) 1996-08-15 2000-12-12 スミスクライン・ビーチャム・コーポレイション Ｉｌ―８レセプターアンタゴニスト
WO1998006262A1 (en) 1996-08-15 1998-02-19 Smithkline Beecham Corporation Il-8 receptor antagonists
AR008290A1 (es) * 1996-08-15 1999-12-29 Smithkline Beecham Corp Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios.
JP2001501918A (ja) * 1996-08-21 2001-02-13 スミスクライン・ビーチャム・コーポレイション Ｉｌ―８レセプターアンタゴニスト
WO1998032439A1 (en) * 1997-01-23 1998-07-30 Smithkline Beecham Corporation Il-8 receptor antagonists
US5929250A (en) * 1997-01-23 1999-07-27 Smithkline Beecham Corporation IL-8 receptor antagonists
US6436927B1 (en) * 1997-02-12 2002-08-20 Smithkline Beecham Corporation IL-8 receptor antagonists
AU8673198A (en) 1997-07-29 1999-02-22 Smithkline Beecham Corporation Il-8 receptor antagonists
AR015426A1 (es) * 1997-09-05 2001-05-02 Smithkline Beecham Corp Compuestos de benzotiazol antagonistas del receptor de il-8, composicion farmaceutica que los contiene, su uso para la manufactura de un medicamento,procedimiento para su preparacion, compuestos intermediarios y procedimiento para su preparacion
AR015425A1 (es) * 1997-09-05 2001-05-02 Smithkline Beecham Corp Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion
AU2234199A (en) 1998-01-16 1999-08-02 Smithkline Beecham Corporation Il-8 receptor antagonists
CA2319063A1 (en) * 1998-01-20 1999-07-22 Katherine L. Widdowson Il-8 receptor antagonists
WO2000006557A1 (en) 1998-07-27 2000-02-10 Smithkline Beecham Corporation Novel process for making il-8 receptor antagonists
JP2003525856A (ja) 1998-08-28 2003-09-02 スミスクライン・ビーチャム・コーポレイション ２−アミノ−５−シアノフェノールの製法
CA2341718A1 (en) 1998-08-28 2000-03-09 Neil H. Baine An improved synthesis of 3-hydroxy-4-amino-benzonitrile
PL198394B1 (pl) * 1998-09-23 2008-06-30 Amgen Inc Związki pochodne arylosulfonoanilidomocznika, ich zastosowanie oraz zawierające je kompozycje farmaceutyczne
UY25842A1 (es) * 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8
CO5170514A1 (es) * 1999-05-28 2002-06-27 Smithkline Beecham Corp Antagonistas de los receptores de la il-8 nistas del receptor de la il-8
US20030225125A1 (en) * 1999-06-16 2003-12-04 Smithkline Beecham Corporation IL-8 receptor antagonists
US6372933B1 (en) * 1999-08-26 2002-04-16 Smithkline Beecham Corporation Process for preparing certain phenyl urea compounds
US6440993B1 (en) * 1999-10-12 2002-08-27 Smithkline Beecham Corporation IL-8 receptor antagonists
US6653347B2 (en) * 2000-03-01 2003-11-25 Smithkline Beecham Corporation IL-8 receptor antagonists
MY133845A (en) * 2000-03-10 2007-11-30 Smithkline Beecham Corp Il-8 receptor antagonists
US20030050298A1 (en) * 2000-03-10 2003-03-13 Palovich Michael R Il-8 receptor antagonists
US6767922B2 (en) * 2000-03-14 2004-07-27 Smithkline Beecham Corporation IL-8 receptor antagonists
US6664259B2 (en) * 2000-03-16 2003-12-16 Smithkline Beecham Corporation Il-8 receptor antagonists
UY26627A1 (es) * 2000-03-24 2001-09-28 Smithkline Beecham Corp Antagonistas de receptores de il-8
AU2001253172A1 (en) * 2000-04-07 2001-10-23 Smith Kline Beecham Corporation Il-8 receptor antagonists
US6432960B2 (en) * 2000-05-10 2002-08-13 Bristol-Myers Squibb Company Squarate derivatives of dihydropyridine NPY antagonists
MXPA02011868A (es) * 2000-05-30 2003-04-10 Smithkline Beecham Corp Antagonistas de receptor de interleucina 8.
WO2002057230A1 (en) * 2001-01-16 2002-07-25 Smithkline Beecham Corporation Il-8 receptor antagonists
WO2002067919A1 (en) * 2001-01-16 2002-09-06 Smithkline Beecham Corporation Il-8 receptor antagonists
EP1355875A1 (en) * 2001-02-02 2003-10-29 Schering Corporation 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists
US20030204085A1 (en) * 2001-02-02 2003-10-30 Taveras Arthur G. 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
KR20030088044A (ko) * 2001-03-30 2003-11-15 스미스클라인 비참 코포레이션 페놀-함유 화합물의 합성 방법
CA2446193C (en) * 2001-06-05 2011-11-01 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused cycloalkyl urea compounds
US20040038854A1 (en) * 2001-07-16 2004-02-26 Dillon Susan B. Use of il-8 receptor antagonists in the treatment of virus infections
US20030032802A1 (en) * 2002-08-30 2003-02-13 Palovich Michael R. IL8-receptor antagonists
US20030028042A1 (en) * 2002-08-30 2003-02-06 Palovich Michael R. Il8-receptor antagonists
US20030065170A1 (en) * 2002-09-05 2003-04-03 Widdowson Katherine Louisa Il-8 receptor antagonists
EP1631559A4 (en) * 2003-06-06 2008-08-27 Smithkline Beecham Corp IL-8 SB / SB RECEPTOR ANTAGONISTS
US20070249625A1 (en) * 2004-10-20 2007-10-25 Jakob Busch-Petersen Il-8 Receptor Antagonists
BRPI0710232B8 (pt) * 2006-04-21 2021-05-25 Glaxosmithkline Llc composto antagonista do receptor de il-8, composição farmacêutica que compreende o dito composto e uso do mesmo para o tratamento de uma doença mediada por quimiocina
CL2007001829A1 (es) 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.

Also Published As

Publication number Publication date
WO2004039775A3 (en) 2004-08-26
EP1558259B1 (en) 2011-04-06
DE60336672D1 (de) 2011-05-19
JP2006506404A (ja) 2006-02-23
DK1558259T3 (da) 2011-07-11
PE20040607A1 (es) 2004-09-18
AR041834A1 (es) 2005-06-01
AU2003287219A1 (en) 2004-05-25
SI1558259T1 (sl) 2011-06-30
MY143477A (en) 2011-05-31
ATE504300T1 (de) 2011-04-15
US20060040952A1 (en) 2006-02-23
AU2003287219A8 (en) 2004-05-25
EP1558259A4 (en) 2009-04-08
EP2388006A1 (en) 2011-11-23
ES2362357T3 (es) 2011-07-04
JP4843220B2 (ja) 2011-12-21
WO2004039775A2 (en) 2004-05-13
US7709485B2 (en) 2010-05-04
TW200418812A (en) 2004-10-01
EP1558259A2 (en) 2005-08-03
US20090093492A1 (en) 2009-04-09
PT1558259E (pt) 2011-06-17

Similar Documents

Publication Publication Date Title
CY1112135T1 (el) Ανταγωνιστες υποδοχεα il-8
CY1113132T1 (el) Ανταγωνιστες υποδοχεα il-8
CY1106514T1 (el) Ανταγωνιστες υποδοχεων il-8
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
CY1108378T1 (el) 4-υποκατεστημενα παραγωγα 1-αμινοκυκλοεξανιου για την χρησιμοποιηση σαν προσδεματα υποδοχεα orl1 ή οπιακου υποδοχεα mu
CY1107505T1 (el) Πουρινικες ενωσεις και χρησεις τους ως προσδεματα υποδοχεων κανναβιδοειδων
CY1106424T1 (el) Παραγωγα ν-φαινυλ-πυρρολ γουανιδινης ως συνδετες υποδοχεις μελανοκορτινης
CY1111317T1 (el) Παραγωγα 4-φαινυλοπυριδινης και χρηση αυτων ως ανταγωνιστων υποδοχεων της νκ-1
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
DE60131967D1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
CY1113413T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξοοξικης πιπεραζινης
CY1105994T1 (el) Aναδιαταγμενες πεντανολες, μεθοδος για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδων
CY1110669T1 (el) Χρησιμοποιηση βενζο-συγχωνευμενων ετεροκυκλικων παραγωγων σουλφαμιδιου για τη θεραπευτικη αγωγη της καταθλιψης
CY1110362T1 (el) Ν-(2-αρυλαιθυλο)βενζυλαμινες ως ανταγωνιστες του 5-ητ6 υποδοχεα
CY1105253T1 (el) Ετepοπολυκυκλικες ενωσεις και η χρησιμοποιηση τους ως ανταγωνιστες μεταβολοτροπου γλουταμινικου υποδοχεως
DK1536827T3 (da) Anvendelse af proteinkinase N-beta
CY1105705T1 (el) Παραγωγα ινδολυλαλκυλαμινης σαν συνδετηρες 5-υδροξυτρυπταμινης-6
CY1109989T1 (el) 3,4-di-υποκαθισταμενες cyclobutene-1,2-diones ως συνδετες του υποδοχεα των cxc-χημειοκινων
NO20060195L (no) Kinolylamidderivater som CCR-5-antagonister
PA8571001A1 (es) 2-(2,6-diclorofenil)-diarilimidazoles
CY1106509T1 (el) Αμιδοακετονιτριλια κατα των παρασιτων του εντερου
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
CY1107985T1 (el) Ccr1 ανταγωνιστες για την αγωγη μεταξυ αλλων απομυελινωτικης φλεγμονωδους νοσου
CY1105734T1 (el) Nεα προ-φαρμακα του 1-μεθυλο-2-(4-αμιδινοφαινυλαμινομεθυλο)-βενζιμιδαζολ-5-υλιο-καρβοξυλικο οξυ-(ν-2-πυριδυλο-ν-2-υδροξυκαρβονυλαιθυλο)-αμιδιου, η παρασκευη και η χρησιμοποιηση τους ως φαρμακων
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto